Introduction
============

Following the T cell activation, cytotoxic T lymphocyte antigen-4 (CTLA-4), a negative regulatory molecule, will be expressed on T cells ^[@B1],[@B2]^. CTLA-4 is a homolog of CD28 but binds B-7 molecules with greater affinity. Inhibitory signals of this molecule inhibit cell cycle progression and IL-2 production, leading to a halt on an ongoing immune response ^[@B3]--[@B6]^.

Regarding the central role of CTLA-4 in down-regulation of the immune responses, co-stimulatory receptors became an important target for drug development. The best example is the CTLA4-Ig fusion protein, containing the extracellular domain of CTLA-4 and the constant region of human IgG antibody. This fusion protein can inhibits T cells dependent immune responses ^[@B5],[@B7],[@B8]^.

In this study we aimed to fuse extracellular domain of *ctla-4* gene to Fc region of human *igg1* gene. This recombinant DNA could be used to produce CTLA4-Ig protein and studding its function in future studies.

Materials and Methods
=====================

Enzymes and chemicals
---------------------

All chemicals and antibiotics were purchased from Sigma, Merck (Germany) and Invitrogen (France), unless stated otherwise. DNA-modifying enzymes and restriction enzymes were obtained from Fermentas.

Vectors, microorganisms and growth conditions
---------------------------------------------

*Escherichia coli* DH5α (CinnaGen, Iran) as a host and pBudCE4.1 as an expression vector were used. IgG1 containing vector was provided kindly by Dr. Rabbani (Avicenna Research Institute, Iran). *Escherichia coli (E. coli)* were cultured in LB medium at appropriate temperature (37*°C*) with shaking (150 *rpm*).

PCR amplification and CTLA4-Ig fragment construction
----------------------------------------------------

Extracellular domain of *ctla-4* gene was amplified using specific primers (CTLA4-FOR/CTLA4-fuse) and pUCCTLA4 vector as template. For subsequent cloning of the PCR-derived fragments, *Sal*I and *Bam*HI restriction sites were added to the 5′-end of these primers, respectively ([Table 1](#T1){ref-type="table"}). pUCCTLA-4 (synthetic construct) was used to amplify the *ctla-4* gene with *pfu* polymerase enzyme. PCR products were purified by High Pure PCR Product Purification Kit (Roche, Germany). The purified fragment was digested simultaneously with vector containing human *igg1* gene using *Sal*I/*BamH*I enzymes and then were ligated. *E. coli* DH5α cells were transformed using CaCl~2~ method ^[@B9]^. Recombinant colonies were confirmed by PCR using specific primers. Plasmid DNA preparation was done using QIAGEN Mini Prep Kit (Germany).

###### 

Oligonucleotides (primers) used in present study (restriction sites were showed in bold)

  **Primers**                                           **Sequence 5′ to 3′**                  **Orientation**   **5′ cloning site**
  ----------------------------------------------------- -------------------------------------- ----------------- ---------------------
  **A) Primers used for amplification of *ctla4-Ig***                                                            
    CTLA-4 FOR                                          5′-TT**GTCGAC**AGCCACCATGGCTTGCCTT-3   Sense             *Sal*I
    CTLA-4 fuse                                         5′-TT**GGATCC**GTCAGAATCTGGGCA-3′      Anti-sense        *Bam*HI
  **B) Universal primers**                                                                                       
    T7f                                                 5′ GTAAAACGACGGCCAGT                   Sense             **\--**
    pBudCE4.1r                                          5′ CAGGAAACAGCTATGAC                   Anti-sense        **\--**
    M13f                                                5′-GTAAAACGACGGCCAGT-3′                Sense             **\--**
    M13r                                                5′-AACAGCTATGACCATG-3′                 Anti-sense        **\--**

Construction of CTLA4-Ig expression vector
------------------------------------------

Vector containing the *ctla4-ig* fragment digested by *Sal*I/*Xba*I enzymes and subcloned into pBudCE4.1 *Sal*I/*Xba*I cloning sites with the methods mentioned before. Recombinant colonies were confirmed by digestion with cloning enzymes and PCR pattern.

Sequence and computer analysis
------------------------------

Cloned DNA fragment in pBudCE4.1 (50--200 *ng/μl*) was sequenced by a Commercial Service (Bioneer, South Korea).

Results
=======

*ctla-4* fragment was amplified using specific primers and *pfu* polymerase. A specific band about 483 *bp* showed the expected size ([Figure 1](#F1){ref-type="fig"}). Extracellular domain of *ctla*-*4* gene was inserted into the *Sal*I and *Bam*HI pGEMIgG vector and designated as pGEMC-TLA4-Ig. The new construct was confirmed by restriction pattern using *Sal*I/*BamH*I and *Sal*I/*Xba*I enzymes and PCR product pattern. According to the size of *ctla-4* gene external domain (483 *bp*) and *igg1* gene (993 *bp*), the resulting fragment (1476 *bp*) confirmed the fusion of extracellular domain of *ctla-4* to human *igg1* gene ([Figure 2](#F2){ref-type="fig"}).

![*ctla-4* gene PCR product with *Pfu* polymerase enzyme M: 1 *kb* ladder\
1: PCR product using specific primers (CTLA4- FOR / CTLA4-fuse).](AJMB-7-179-g001){#F1}

![Confirmation of new construct with digestion pattern\
A) 1: Digestion of vector containing *igg1* gene with *Sal*I/*Xba*I enzymes\
2. Digestion of new construct with *Sal*I/*Xba*I enzymes\
B) 1: Digestion of new construct with *Sal*I/*Bam*HI enzymes.](AJMB-7-179-g002){#F2}

To clone *ctla4-ig* fragment in pBudCE4.1 expression vector, pGEMCTLA4-Ig construct was digested and gel purified fragment was cloned into pBudCE4.1 vector. Construction of the expression vector was confirmed by restriction pattern analysis using *Sal*I and *Xba*I. The cloned fragment was sequenced by T7f/p-BudCE4.1r universal primers. DNA sequencing showed an open reading frame, 1476 *bp* in length, encoding a 492 amino acid polypeptide. The new construct designated pBudTJ1 is shown in [figure 3](#F3){ref-type="fig"}.

![pBudTJ1 schematic view.](AJMB-7-179-g003){#F3}

Discussion
==========

Co-stimulatory molecules play a critical role in controlling the immune response. The central role of CD28 family, especially the CTLA-4, makes it a useful tool for immunotherapy in autoimmune disease and transplant rejection ^[@B6],[@B10]^.

Two approaches have been selected in respect to the potential clinical applications of CTLA-4 in immunotherapy, anti CTLA-4 antibody and CTLA4-Ig, respectively ^[@B7],[@B11]^. CTLA4-Ig is a fusion protein containing the extracellular domain of CTLA-4 and the Fc portion of human IgG1. This protein is capable of preventing the stimulatory effect of CD28 through competing and binding to B-7s on APCs ^[@B12]--[@B14]^.

In this study, we have fused the extracellular domain of CTLA-4 to the Fc fragment of the human IgG1 antibody. The resulting construct was ligated to pBud-CE4.1 expression vector and confirmed by sequencing. Analysis of the fusion sequence revealed an open reading frame encoding a protein of 445 amino acids with predicted molecular mass of about 50 *kDa* without glycosylation (ExPASy). In subsequent study, this recombinant DNA can be used to produce CTLA4-Ig recombinant protein.
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